RxDoctor Payments Data

Robert Morse, DO

Cardiovascular Disease · Astoria, ORNPI 1174555312

Payments from drug & device makers

$788in general payments, 2019–2025

Across 48 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$278
  • Pfizer$119
  • Johnson & Johnson$66
  • AstraZeneca$63
  • E.r. Squibb & Sons, L.L.C.$62
  • Amgen$49
  • plus $152 from 6 others

What the payments were for

  • Food & beverage$77598%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$788 in reported general payments places this provider in the 40th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$84,333
Medicare patients
1,094
Services billed
2,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban630$721,363
JardianceEmpagliflozin210$186,264
XareltoRivaroxaban139$156,875
EntrestoSacubitril/Valsartan130$114,650
FarxigaDapagliflozin Propanediol66$52,924
Repatha SureclickEvolocumab57$43,781
Repatha SyringeEvolocumab20$23,814
Metoprolol Succinate795$15,532
Atorvastatin Calcium666$7,387
Praluent PenAlirocumab14$6,671
Rosuvastatin Calcium315$4,746
Losartan Potassium278$3,854
Valsartan156$3,735
Bumetanide103$3,516
Ezetimibe147$3,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$721,363630 claims
Boehringer IngelheimJardiance$35$186,264210 claims
Johnson & JohnsonXarelto$66$156,875139 claims
NovartisEntresto$278$114,650130 claims
AstraZenecaFarxiga$63$52,92466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Astoria

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →